Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Exocrine Pancreatic Insufficiency Epidemiology Forecast

DelveInsight’s ‘Exocrine Pancreatic Insufficiency (EPI) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Exocrine Pancreatic Insufficiency (EPI) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Exocrine Pancreatic Insufficiency (EPI) Understanding

The pancreas is a dual function organ that possesses both exocrine and endocrine components that are critical for the digestion, absorption, and metabolism of nutrients. Normal digestion requires the exocrine function of the pancreas for macronutrient digestion. Primarily, this occurs via. enzymatic hydrolysis by pancreatic enzymes, in particular lipase, amylase, and proteases (trypsin and chymotrypsin). Exocrine pancreatic insufficiency (EPI) refers to the presence of maldigestion and malabsorption of such nutrients. It is a consequence of the primary loss of functional parenchyma and/or secondarily impaired exocrine pancreatic function and insufficient pancreatic enzyme activity.  


EPI is sometimes defined simply as an enzyme output less than 10% of that necessary to sustain normal digestion; however, there is no consensus in the literature on the definition of EPI. Furthermore, the clinical presentation of EPI can vary widely depending on the underlying cause, as well as disease stage, diet, and other factors. EPI is most commonly caused by diseases that destroy the pancreatic parenchyma, such as chronic pancreatitis and cystic fibrosis, as well as pancreatic resection. The incidence of EPI in chronic pancreatitis ranges from 30% of patients with mild disease to 85% with severe disease. Approximately 85% of infants with cystic fibrosis have EPI at birth.

Exocrine Pancreatic Insufficiency (EPI) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Causative Indications of EPI and Prevalence of Exocrine Pancreatic Insufficiency scenario of Exocrine Pancreatic Insufficiency (EPI) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Exocrine Pancreatic Insufficiency (EPI) Detailed Epidemiology Segmentation

  • In the 7MM, the highest prevalence of Causative Indications of EPI was observed in Type 2 Diabetes Mellitus which was estimated to be 67,892,836 cases in 2017 during the forecast period (2020–2030).
  • As per the estimates in Japan, 61,961, 66,261, 11,721, 25,319 patients were affected by Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis and Unresectable Pancreatic Cancer in 2017, respectively, which are anticipated to increase in the forecast period.
  • Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis and Unresectable Pancreatic Cancer are assumed to play the foremost role in the development of EPI.

Scope of the Report

  • The report covers the descriptive overview of Exocrine Pancreatic Insufficiency (EPI), explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Exocrine Pancreatic Insufficiency (EPI).
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Exocrine Pancreatic Insufficiency (EPI), Total Diagnosed and Treated Cases of Exocrine Pancreatic Insufficiency (EPI).

Report Highlights

  • Eleven Year Forecast of Exocrine Pancreatic Insufficiency (EPI)
  • 7MM Coverage
  • Prevalence of Causative Indications of EPI
  • Prevalence of Exocrine Pancreatic Insufficiency

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Exocrine Pancreatic Insufficiency (EPI)?
  • What is the historical Exocrine Pancreatic Insufficiency (EPI) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Exocrine Pancreatic Insufficiency (EPI) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Exocrine Pancreatic Insufficiency (EPI)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Exocrine Pancreatic Insufficiency (EPI) during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy

The Exocrine Pancreatic Insufficiency (EPI) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Exocrine Pancreatic Insufficiency (EPI) market.
  • Quantify patient share distribution in the 7MM for Exocrine Pancreatic Insufficiency (EPI).
  • The Exocrine Pancreatic Insufficiency (EPI) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Exocrine Pancreatic Insufficiency (EPI) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary

3. SWOT Analysis

4. Exocrine Pancreatic Insufficiency (EPI) Overview at a Glance

4.1. Patient Share (%) Distribution of Exocrine Pancreatic Insufficiency (EPI) in 2017

4.2. Patient Share (%) Distribution of Exocrine Pancreatic Insufficiency (EPI) in 2030

5. Disease Background and Overview: Exocrine Pancreatic Insufficiency (EPI)

5.1. Introduction

5.2. Biology and pathology of Exocrine Pancreatic Insufficiency

5.3. Pathophysiology of EPI

5.4. Causes and Risk Factors of EPI

5.4.1. EPI caused by pancreatic disorders

5.4.2. EPI caused by extrapancreatic disorders

5.5. Serum nutritional markers for prediction of pancreatic exocrine insufficiency in chronic pancreatitis

5.5.1. Disorders of Carbohydrate Metabolism

5.5.2. Disorders of Lipid Metabolism

5.6. Diagnosis

5.6.1. Fecal elastase-1 test (FE-1)

5.6.2. Serum trypsinogen

5.6.3. Fecal chymotrypsin

5.6.4. Breath tests

5.6.5. Coefficient of fat absorption (CFA)

5.6.6. Preoperative Evaluation

5.6.7. Direct pancreatic function test

5.6.8. Secretin-enhanced magnetic resonance cholangiopancreatography (MRCP)

5.6.9. Differential Diagnosis of exocrine pancreatic insufficiency

6. Recognized Establishments

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. 7 Major Markets

7.2.1. Prevalence of Causative Indications of EPI in the 7MM

7.2.2. Prevalence of Exocrine Pancreatic Insufficiency in the 7MM

8. Country-wise Epidemiology of Exocrine Pancreatic Insufficiency (EPI)

8.1. Assumption and Rationale

8.2. United States

8.2.1. Prevalence of Causative Indications of EPI in the United States

8.2.2. Prevalence of Exocrine Pancreatic Insufficiency in the United States

8.3. EU5 Countries

8.3.1. Germany

8.3.1.1. Prevalence of Causative Indications of EPI in Germany

8.3.1.2. Prevalence of Exocrine Pancreatic Insufficiency in Germany

8.3.2. France

8.3.2.1. Prevalence of Causative Indications of EPI in France

8.3.2.2. Prevalence of Exocrine Pancreatic Insufficiency in France

8.3.3. Italy

8.3.3.1. Prevalence of Causative Indications of EPI in Italy

8.3.3.2. Prevalence of Exocrine Pancreatic Insufficiency in Italy

8.3.4. Spain

8.3.4.1. Prevalence of Causative Indications of EPI in Spain

8.3.4.2. Prevalence of Exocrine Pancreatic Insufficiency in Spain

8.3.5. The United Kingdom

8.3.5.1. Prevalence of Causative Indications of EPI in the United Kingdom

8.3.5.2. Prevalence of Exocrine Pancreatic Insufficiency in the United Kingdom

8.4. Japan

8.4.1. Assumption and Rationale

8.4.2. Prevalence of Causative Indications of EPI in Japan

8.4.3. Prevalence of Exocrine Pancreatic Insufficiency in Japan

9. Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Table

Table 1: Summary of Exocrine Pancreatic Insufficiency (EPI) Epidemiology, and Key Events (2017–2030)

Table 2: Summary of Exocrine Pancreatic Insufficiency (EPI) in the 7MM, and Key Events (2017–2030)

Table 3: Common symptoms shared by EPI and other gastrointestinal conditions

Table 4: EPI caused by pancreatic disorders

Table 5: EPI caused by extrapancreatic disorders

Table 6: Pancreatic Function Tests—Indirect and Direct Tests

Table 7: Prevalence of Causative Indications of EPI in the 7MM (2017–2030)

Table 8: Prevalence of Exocrine Pancreatic Insufficiency in the 7MM (2017–2030)

Table 9: Prevalence of exocrine pancreatic insufficiency in individuals with predisposing conditions

Table 10: Prevalence of Causative Indications of EPI in the United States (2017–2030)

Table 11: Prevalence of Exocrine Pancreatic Insufficiency in the United States (2017–2030)

Table 12: EPI caused by pancreatic disorders

Table 13: Prevalence of Causative Indications of EPI in Germany (2017–2030)

Table 14: Prevalence of Exocrine Pancreatic Insufficiency in Germany (2017–2030)

Table 15: Prevalence of Causative Indications of EPI in France (2017–2030)

Table 16: Prevalence of Exocrine Pancreatic Insufficiency in France (2017–2030)

Table 17: Prevalence of Causative Indications of EPI in Italy (2017–2030)

Table 18: Prevalence of Exocrine Pancreatic Insufficiency in Italy (2017–2030)

Table 19: Prevalence of Causative Indications of EPI in Spain (2017–2030)

Table 20: Prevalence of Exocrine Pancreatic Insufficiency in Spain (2017–2030)

Table 21: Prevalence of Causative Indications of EPI in the United Kingdom (2017–2030)

Table 22: Prevalence of Exocrine Pancreatic Insufficiency in the United Kingdom (2017–2030)

Table 23: Prevalence of Causative Indications of EPI in Japan (2017–2030)

Table 24: Prevalence of Exocrine Pancreatic Insufficiency in Japan (2017–2030)

List of Figures

Figure 1: Exocrine Pancreatic Insufficiency SWOT Analysis

Figure 2: The pathology of exocrine pancreatic insufficiency

Figure 3: Relationship between extrapancreatic diseases/conditions and PEI.

Figure 4: Basis of pancreatic function breath tests.

Figure 5: Prevalence of Causative Indications of EPI in the 7MM (2017–2030)

Figure 6: Prevalence of Exocrine Pancreatic Insufficiency in the 7MM (2017–2030)

Figure 7: Prevalence of Causative Indications of EPI in the United States (2017–2030)

Figure 8: Prevalence of Exocrine Pancreatic Insufficiency in the United States (2017–2030)

Figure 9: Prevalence of Causative Indications of EPI in Germany (2017–2030)

Figure 10: Prevalence of Exocrine Pancreatic Insufficiency in Germany (2017–2030)

Figure 11: Prevalence of Causative Indications of EPI in France (2017–2030)

Figure 12: Prevalence of Exocrine Pancreatic Insufficiency in France (2017–2030)

Figure 13: Prevalence of Causative Indications of EPI in Italy (2017–2030)

Figure 14: Prevalence of Exocrine Pancreatic Insufficiency in Italy (2017–2030)

Figure 15: Prevalence of Causative Indications of EPI in Spain (2017–2030)

Figure 16: Prevalence of Exocrine Pancreatic Insufficiency in Spain (2017–2030)

Figure 17: Prevalence of Causative Indications of EPI in the United Kingdom (2017–2030)

Figure 18: Prevalence of Exocrine Pancreatic Insufficiency in the United Kingdom (2017–2030)

Figure 19: Prevalence of Causative Indications of EPI in Japan (2017–2030)

Figure 20: Prevalence of Exocrine Pancreatic Insufficiency in Japan (2017–2030)

Forward to Friend

Need A Quote